Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases.
Helen R GosseltJette A van LintLeanne J KossePhyllis I SpulsHarald E VonkemanSander W TasFrank HoentjenMichael T NurmohamedBart J F van den BemtMartijn Bastiaan Adriaan van DoornNaomi T JessurunPublished in: Expert opinion on drug safety (2023)
Sex differences in the frequency and nature of ADRs, but not in ADR burden, exist during treatment with adalimumab and etanercept in patients with inflammatory rheumatic diseases. This should be taken into consideration when investigating and reporting results on ADRs and when counseling patients in daily clinical practice.
Keyphrases
- adverse drug
- rheumatoid arthritis
- juvenile idiopathic arthritis
- clinical practice
- end stage renal disease
- ejection fraction
- newly diagnosed
- electronic health record
- ankylosing spondylitis
- chronic kidney disease
- emergency department
- prognostic factors
- physical activity
- risk factors
- drug induced
- patient reported outcomes
- smoking cessation
- human immunodeficiency virus
- hidradenitis suppurativa
- antiretroviral therapy